Not Signed In - Lexicon Advances LX6171 For Cognitive Disorders Into Phase 1b Clinical Trial
Wed, 31 Jan 2007 08:00 AM EST
... Lexicon Genetics Incorporated (Nasdaq: LEXG) announced today that it has initiated a Phase 1b clinical trial of LX6171, its oral drug candidate for the treatment of cognitive impairment associated with disorders such as Alzheimer's disease, schizophrenia and vascular dementia. [click link for full article] ...
Related Topics
- Clinical Trials
- Behavioral Disorders
- Cognitive behavior therapy
- Traumatic Brain Injury: Cognitive and Communication Disorders
- Pharmacology
- Trastuzumab
- Psychopharmacology
- Tarceva
- Personality Disorders
- Depression
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Clinical Growth Charts
- Bevacizumab Injection
- Crohn's Disease
- Pancreatic Cancer
- Interferon Gamma-1b Injection
- Achondrogenesis, type 1B
- Patient Issues
- Cognitive Restructuring
email this page
print this page
bookmark this page
feedback on this page
